A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
Phase of Trial: Phase III
Latest Information Update: 30 Jun 2018
At a glance
- Drugs Insulin degludec/liraglutide (Primary) ; Insulin degludec; Liraglutide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DUAL I China
- Sponsors Novo Nordisk
- 10 Jan 2018 Planned End Date changed from 14 Jan 2019 to 29 Jul 2019.
- 09 Nov 2017 Planned End Date changed from 30 Dec 2018 to 14 Jan 2019.
- 06 Jun 2017 New trial record